Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Candesartan Cilexetil

    Menu

    Candesartan Cilexetil

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Apontis Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights

              Details:

              The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).

              Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Midas Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AstraZeneca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

              Details:

              AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).

              Lead Product(s): Candesartan Cilexetil

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

              Deal Size: $400.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment January 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AstraZeneca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

              Details:

              AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

              Lead Product(s): Candesartan Cilexetil

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

              Deal Size: $400.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment October 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY